Global Ganja Report

A little New York-California cross-fertilization of herbal consciousness took place as Martin Lee, the author of Smoke Signals: A Social History of Marijuana, spoke in Manhattan's East Village the night of Nov. 10 on "The Future of CBD and Medicinal Cannabis." Lee discussed his current work with California-based Project CBD, dedicated to promoting and publicizing research into the medical uses of cannabidiol, and Emerald Pharms, his CBD-oriented dispensary in Hopland, southern Medocino County. The event was hosted by The Alchemist's Kitchen, a New Age-flavored herbal apothecary—or "botanical dispensary"—on East 1st Street. Under New York state's medical marijuana law, the Kitchen recently launched a Bowery Cannabis Club, which specializes in CBD products.

The British government's Medicines & Healthcare Regulatory Agency (MHRA) on Oct. 11 issued a finding that cannabidiol (CBD) has a "restoring, correcting or modifying" effect on "physiological functions." The Independent calls the move "a potential milestone in the campaign to legalise cannabis and bring about evidence-based laws regarding drugs."  The review of CBD, a non-psychoactive cannabinoid increasingly studied for its therapeutic value, was undertaken following discussions with MediPen, a London-based company that seeks to market a CBD vaporizer.

Researchers at Stanford University have developed a "potalyzer"—a device that can detect human THC levels, so cops can determine if a motorist is too impaired to drive. The hand-held device uses sophisticated bio-sensors to detect THC molecules in saliva. Police officers will supposedly be able collect a spit sample with a cotton swab and read the results on a smartphone or laptop in just three minutes.

After much speculation that the US Drug Enforcement Agency (DEA) would reschedule cannabis this summer, the agency on Aug. 11 dashed petitioners' hopes, rejecting their request to remove its classification as a Schedule I dangerous drug. The DEA denied two separate requests by former state governors to re-classify cannabis as a Schedule II drug or lower. The agency stated (PDF) that the Department of Health and Human Services (HHS) has "concluded that marijuana has high potential for abuse, has no accepted medical use in the United States, and lacks an acceptable level of safety for use even under medical supervision." Tthe DEA did propose a new policy that would allow universities to apply to grow cannabis for research. Until now, the University of Mississippi had a monopoly on cultivation for study. (Jurist)

As Canada prepares to legalize cannabis nationwide, Ottawa is consulting citizens and stake-holders to shape the new policy. Among the proposals floated at a Vancouver Cannabis Hemp Conference this weekend was a measure to cap the THC content of approved strains. Not surprisingly, this met with a resounding negative from industry and advocates. "It's time for us to stop demonizing THC. We need policy that's based on both evidence and expertise," Hilary Black of the BC Compassion Club Society told the CBC.  "We have an opportunity in Canada right now to be leaders on the world stage and to do this right."

The Internet is atwitter over a June 19 report in the Santa Monica Observer with the headline: "US Gov't Will Legalize Marijuana on August 1." The article claims that "weed will soon be legal in all 50 states, with a prescription," thanks to the imminent government action, with cannabis about to be switched from Schedule I to Schedule II. An unnamed DEA attorney is quoted as saying: "Whatever the law may be in California, Arizona or Utah or any other State, because of Federal preemption this will have the effect of making THC products legal with a prescription, in all 50 states." The story also cites a June 17 article in the Denver Post asserting (with no attribution) that the DEA will issue a decision in the matter by July 1.

A group of 22 medical experts convened by Johns Hopkins University and The Lancet, Britain's foremost medical journal, on March 24 issued a call for the decriminalization of all non-violent drug use and possession, flatly calling the international war on drugs a failure. The paper by the Johns Hopkins-Lancet Commission on Public Health and International Drug Policy (PDF) calls on the world's governments to "move gradually toward regulated drug markets and apply the scientific method to their assessment." Dr. Chris Beyrer, a professor at Johns Hopkins Bloomberg School of Public Health and the senior author of the report, told the CBC: "We've had three decades of the war on drugs, we've had decades of zero-tolerance policy. It has had no measurable impact on supply or use, and so as a policy to control substance use it has arguably failed. It has evidently failed."

The trial of a paralyzed man who was prosecuted by Swedish authorities for self-medicating with cannabis has sparked debate over legalization in the Scandinavian nation, according to a March 27 report in Sweden's English-language The Local. Andreas Thörn, 37, who broke his neck in a motorcycle accident in 1994, used cannabis for relief from neuropathic pain as well as anxiety and depression. He was initially acquitted in August 2015 after successfully using a medical defense. Thörn said he had tried numerous pharmaceuticals which did not help, and had run out of legal options. Claes Hultling, spinal injury specialist at the Karolinska Institute, testified that studies indicate barely a fifth of spinal cord patients can be treated with the drugs available today.